One Pharma Giant Is Pressing On 3 Ceilings At Once

In January 2023, AbbVie (ABBV) lost its crown jewel.

Humira, the drug that once brought in more than half of the company's revenue, lost its U.S. patent protection, and cheaper copies flooded in. Sales have been falling ever since, and in the second quarter they dropped another 36% to $756 million.

And yet AbbVie is pressing against its all-time high.

The company rebuilt. Two newer drugs, Skyrizi and Rinvoq, brought in about $8 billion in the second quarter alone, more than 10 times what Humira made, and total revenue grew 10% to nearly $17 billion.

AbbVie isn't alone. Biotech and pharma stocks have been relative strength leaders in 2026, as pipelines are being rebuilt and AI begins to reshape the industry.

Price action is now aligning with the story. 

AbbVie has spent 10 days pinned just under $270, where three separate ceilings are stacked within about a dollar and a quarter of each other: the top Bollinger Band at $268.77, the all-time high at $269.39, and round-numbered resistance at $270.

I call that a triple trigger. When all three give way at once, I expect a surge in volatility to higher prices as investors chase the stock.

The momentum’s already there. Both the 20-day and 50-day moving averages are trending higher, and options traders are increasingly betting on a breakout by November expiration.